Amit K Goyal

Dr. Amit K Goyal


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
GAGagandeep
Gagandeep
TGTarun Garg
Tarun Garg
BMBasant Malik
Basant Malik
GRGoutam Rath
Goutam Rath
AGAmit K Goyal
Amit K Goyal

1 January 2016 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
GRGoutam Rath
Goutam Rath
THTaqadus Hussain
Taqadus Hussain
GCGaurav Chauhan
Gaurav Chauhan
TGTarun Garg
Tarun Garg
AGAmit K Goyal
Amit K Goyal

1 January 2017 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
GCGaurav Chauhan
Gaurav Chauhan
VCVianni Chopra
Vianni Chopra
ATAmit Tyagi
Amit Tyagi
GRGoutam Rath
Goutam Rath
RSRakesh Sharma
Rakesh Sharma
AGAmit K Goyal
Amit K Goyal

22 August 2014 in Drug Delivery
Verified
Journal Article
Closed access
PDF file
HMHarneet Marwah
Harneet Marwah
TGTarun Garg
Tarun Garg
GRGoutam Rath
Goutam Rath
AGAmit K Goyal
Amit K Goyal
The main object of this current research was to examine transferosomes as a transdermal delivery system for insulin, to overwhelm the difficulties related with its subcutaneous delivery. Transferosomal gel formulations were prepared by rotary evaporation sonication technique. The result revealed that insulin was successfully entrapped (78%) in optimized formulations (2.5 I.U. of the drug and 25% of sodium cholate) with cumulative percent drug release (83.11 ± 3.782). The glucose lowering study revealed that the transferosomal gel with chemical penetration enhancer showed better glucose lowering effect as compared to the control gel. Consequently, this study authenticated that the transferosomal gel can be used as a possible substitute to the conventional formulations of insulin with progressive permeation characteristics for transdermal application.

11 August 2014 in Drug Delivery
Verified
Journal Article
Open access
PDF file
JSJagdeep Singh
Jagdeep Singh
TGTarun Garg
Tarun Garg
GRGoutam Rath
Goutam Rath
AGAmit K Goyal
Amit K Goyal
From the early sixteenth and seventeenth centuries to the present day of life, tuberculosis (TB) still is a global health threat with some new emergence of resistance. This type of emergence poses a vital challenge to control TB cases across the world. Mortality and morbidity rates are high due to this new face of TB. The newer nanotechnology-based drug-delivery approaches involving micro-metric and nano-metric carriers are much needed at this stage. These delivery systems would provide more advantages over conventional systems of treatment by producing enhanced therapeutic efficacy, uniform distribution of drug molecule to the target site, sustained and controlled release of drug molecules and lesser side effects. The main aim to develop these novel drug-delivery systems is to improve the patient compliance and reduce therapy time. This article reviews and elaborates the new concepts and drug-delivery approaches for the treatment of TB involving solid-lipid particulate drug-delivery systems (solid-lipid micro- and nanoparticles, nanostructured lipid carriers), vesicular drug-delivery systems (liposomes, niosomes and liposphere), emulsion-based drug-delivery systems (micro and nanoemulsion) and some other novel drug-delivery systems for the effective treatment of tuberculosis and role of immunomodulators as an adjuvant therapy for management of MDR-TB and XDR-TB.

5 October 2015 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
AGAmit K Goyal
Amit K Goyal
TGTarun Garg
Tarun Garg
GRGoutam Rath
Goutam Rath
UGUmesh Datta Gupta
Umesh Datta Gupta
PGPushpa Gupta
Pushpa Gupta